TOTAL: $880.595M


Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)


Adherex Technologies Inc. (Chapel Hill, N.C.)

Rights distribution

Units

C$12.75 ($12.9)

Adherex will raise $12.9M in a distribution of rights to purchase shares of common stock at C3 cents per unit (2/15)

Aeterna Zentaris (Quebec City)

Equity line

12.5S

(up to $19.8)

Aeterna entered an at-the-market sales agreement with McNicoll, Lewis & Vlak LLC to offer from time to time up to 12.5M shares (1/24)

Angel Biotechnology Holdings plc (Edinburgh, Scotland)

Private placement

N/A

£1.94 ($3.1)

Angel raised $3.1M in a placement (2/2**)

Biovest International Inc. (Tampa, Fla.)

Loan

N/A

$1.5

Biovest received a loan from the state of Minnesota, the city of Coon Rapids and real estate developer JMS Holdings LLC (2/25)

Cell Therapeutics Inc. (Seattle)

Private placement of Series 10 nonconvertible preferred stock and warrants

S and W for 25.9S

$25

Cell Therapeutics sold $25M worth of the preferred stock, with warrants for up to 25.9M shares and additional rights to purchase another $25M worth of shares of Series 11 convertible preferred stock to a certain institutional investor (2/22)

EpiCept Corp. (Tarrytown, N.Y.)

Private placement

8.9S and W for 3.6S

$7.14

EpiCept raised $7.14M through the placement through agent Rodman & Renshaw (2/9)

eTherapeutics plc (Newcastle, UK)

Private placement

67.7S

£17.6 ($28.2)

eTherapeutics raised $28.2M in the placement of $33.6M in shares, with some proceeds going to shareholders (2/16)

Fibrocell Science Inc. (Exton, Pa.)

Private placement of Series D convertible preferred stock

N/A

$7.8

Fibrocell raised $7.8M in the placement with certain investors (2/17)

ImmunoCellular Therapeutics Ltd. (Los Angeles)

Private placement of units

5.2U

$8.1

ImmunoCellular is selling 5.2M units, each comprising one share of common stock and one warrant to purchase one-half share of common stock – sold at $1.55 each (2/24)

Intercell AG (Vienna, Austria)

Placement of senior unsecured convertible notes

Notes

€33 ($45.37)

Intercell placed the notes in a private placement (2/24)

NovaDel Pharma Inc. (Bridgewater, N.J.)

Private placement of preferred stock

Series A convertible preferred stock

$1.6

NovaDel raised $1.6M in gross proceeds through the sale of 1,667 shares of stock to institutional investors (2/16)

Oncothyreon Inc. (Seattle)

Loan facility

N/A

$5

Oncothyreon entered a $12.5M loan facility with General Electric Corp., and drew down $5M (2/10)

PharmaGap Inc. (Ottawa, Ontario)

Private offering of equity units

7.6U

$0.836

PharmaGap completed the initial closing in the gross amount of $835,725 (2/24)

Poniard Pharmaceuticals Inc. (San Francisco)

Committed equity financing facility

4.9S

$1.9

Poniard received $1.9M under its facility with Small Cap Biotech Value Ltd. (2/10)

Pro-Pharmaceuticals Inc. (Newton, Mass.)

Warrant and stock option exercises and sale of Series C preferred stock

4.9S

$5.05

Pro-Pharmaceuticals issued about 4.9M shares from warrant and stock option exercises for $2.8M and raised about $2.25M from the sale of Series C preferred stock (2/11)

Proteonomix Inc. (Mountainside, N.J.)

Private placement of preferred and common stock

8.8S and 11.5S

$37.7

Proteonomix raised $37.7M by placing 8.8M shares of preferred stock and 11.5M shares of common stock (2/3)

Rosetta Genomics Ltd. (Rehovot, Israel)

Private placement and registered direct offering

4.5S and 5.5S and W for 3.4S and 2.7S

$6

Rosetta raised $6M, selling 4.5M shares in the private placement and 5.5M shares in the registered direct offering for 60 cents per share; purchasers also get five-year warrants for 3.4M shares in the private placement and 2.7M shares in the direct offering; Rodman & Renshaw LLC is the sole agent for the offerings (2/18)

Sareum plc (Cambridge, UK)

Private placement

50S

£0.5 ($0.799)

Sareum raised $799,000 in a placing of 50M new ordinary shares (2/16**)

SemBioSys Genetics Inc. (Calgary, Alberta)

Placement of bonds

N/A

C$4 ($4.1)

SemBioSys entered a commitment for up to $4.1M in financing; Concept Capital Management Ltd. agreed to extend a secured loan facility to the company of $300,000 a month at an interest rate of 7% per annum (2/14)

Sirona Biochem Corp. (Vancouver, British Columbia)

Private placement of units

10U

C$2.5 ($2.5)

Sirona raised $2.5M by placing 10M units at C25 cents each (2/25)

Somaxon Pharmaceuticals Inc. (San Diego)

Revolving line of credit

N/A

(up to $15M)

Somaxon obtained the credit line from Comerica Bank (2/9)

TiGenix NV (Leuven, Belgium)

Rights issue

N/A

€15 ($20.7)

TiGenix raised $20.7M in a rights offering (2/28)

Valeant Pharmaceuticals International Inc. (Mississauga, Ontario)

Placement of 6.75% senior unsecured notes

N/A

$650

Valeant placed the notes with institutional investors (2/7)

ValiRx plc (London)

Private placement of common stock

549.5S

$5.3

ValiRx raised $5.3M by placing the shares (2/17)


Notes:

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed.

** Denotes the date the item ran in BioWorld International. Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

N/A = Not applicable; ND = Not disclosed.